Richardson Lectures on Ancillary-Care Obligations April 8
Henry Richardson, PhD, professor of philosophy and senior research scholar with the Kennedy Institute of Ethics at Georgetown University, will address the ancillary-care obligations of researchers in two talks on Friday, April 8.
The first talk will be for CCTST Grand Rounds on the medical campus, where Richardson will present "Global Bioethics and the Ancillary-Care Obligations of Biomedical Researchers from noon-1 p.m. in MSB 3351. Lunch will be available to participants who register online.
The second talk takes place on main campus, where he will present "Locating Medical Researchers' Ancillary-Care Obligations Within the Division of Moral Labor" in Room 427 of Tangeman University Center (TUC) from 4 p.m. – 6 p.m. Registration is not required.
Richardson is the editor of Ethics and author of the 2012 book Moral Entanglements: The Ancillary-Care Obligations of Medical Researchers (Oxford University Press).
Free and open to the public, the talks are organized by the Global Bioethics Workgroup and co-sponsored by the Center for Clinical and Translational Science and Training (CCTST), CCHMC Ethics Center, Taft Medical Humanities Group, and UC Department of Philosophy. For more information, visit the CCTST website or contact Koffi Maglo, PhD.
Related Stories
How to make the most out of any networking event
Get practical networking event tips for college students. Learn how to prepare, introduce yourself, and make meaningful connections.
From first-gen student to aerospace leader: Angela Hall named UC...
June 18, 2025
After starting over at 25, Hall climbed from front desk to chief of staff — and now helps lead a $1.8 billion defense program at GE Aerospace, proving that determination and a UC Clermont degree can take you anywhere.
Novel drug achieves high objective response rate in heavily...
June 18, 2025
Cancer Network News highlighted research led by the University of Cincinnati Cancer Center's Zulfa Omer that found a novel drug was generally well tolerated and demonstrated early efficacy in patients with relapsed/refractory chronic lymphocytic leukemia.